Pfizer Invests $120 Million in Four Clinical-stage Biotech Companies Through the Pfizer Breakthrough Growth Initiative

The Pfizer Breakthrough Growth Initiative has invested a total of $120 million into four separate clinical-stage biotech companies. Pfizer anticipates the initiative to invest up to half-a-billion dollars in small- to medium-sized companies developing clinical-stage assets aligned with Pfizer’s core areas of focus.
Read more...

;